InnoCare Pharma's novel CDH17-targeting ADC, ICP-B208, has administered its first dose to a patient.
InnoCare Pharma (SSE: 688428; HKEX: 09969) announced that its independently developed novel antibody-drug conjugate (ADC), ICP-B208, which targets CDH17, has administered its first dose to a patient.
Built on InnoCare Pharma’s proprietary ADC technology platform, ICP-B208 consists of a humanized anti-CDH17 antibody linked via a protease-cleavable linker to a potent payload independently developed by the company, enabling precise targeting of tumor cells while minimizing off-target effects to the greatest extent possible.
CDH17 belongs to the cadherin family and plays a key role in tumor cell proliferation, migration, and metastasis. It is highly expressed specifically in various gastrointestinal solid tumors such as colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract cancer, making it one of the most promising emerging targets in the global ADC field. Currently, there are no CDH17-targeting ADC drugs on the market worldwide.
Dr. Jasmine Cui, Co-founder, Chairperson, and CEO of InnoCare Pharma, said, 'Following our novel B7-H3-targeting ADC, ICP-B794, we are pleased to see our second ADC candidate advancing rapidly in clinical development. Leveraging our proprietary and differentiated ADC platform, we have developed multiple ADC candidates that demonstrate both potent anti-tumor activity and favorable safety profiles, aiming to deliver better innovative treatment options for cancer patients worldwide.'
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments
to post a comment